Should intravenous iron be the standard of care in oncology?

被引：23

作者：

Auerbach, Michael ^{[1
]}

机构：

[1] Georgetown Univ, Dept Med, Washington, DC 20057 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 10期

关键词：

D O I：

10.1200/JCO.2007.15.4609

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1579 / 1581

页数：3

共 16 条

[1] Erythropoietin for end-stage renal disease [J].

Adamson, JW ;

Eschbach, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :625-627

[2] Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].

Auerbach, M ;

Ballard, H ;

Trout, JR ;

McIlwain, M ;

Ackerman, A ;

Bahrain, H ;

Balan, S ;

Barker, L ;

Rana, J .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307

[3]

AUERBACH MA, 2007, ANN M AM COLL CLIN P

[4] Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia [J].

Bastit, Laurent ;

Vandebroek, An ;

Altintas, Sevilay ;

Gaede, Bernd ;

Pinter, Tamas ;

Suto, Tamas S. ;

Mossman, Tony W. ;

Smith, Kay E. ;

Vansteenkiste, Johan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1611-1618

[5] Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia [J].

Cersosimo, RJ ;

Jacobson, DR .

ANNALS OF PHARMACOTHERAPY, 2006, 40 (01) :58-65

[6] Update on adverse drug events associated with parenteral iron [J].

Chertow, GM ;

Mason, PD ;

Vaage-Nilsen, O ;

Ahlmén, J .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) :378-382

[7] Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study [J].

Coyne, Daniel W. ;

Kapoian, Toros ;

Suki, Wadi ;

Singh, Ajay K. ;

Moran, John E. ;

Dahl, Naomi V. ;

Rizkalal, Adel R. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03) :975-984

[8] Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy [J].

Crawford, J ;

Cella, D ;

Cleeland, CS ;

Cremieux, PY ;

Demetri, GD ;

Sarokhan, BJ ;

Slavin, MB ;

Glaspy, JA .

CANCER, 2002, 95 (04) :888-895

[9] Suspected iron dextran-related adverse drug events in hemodialysis patients [J].

Fletes, R ;

Lazarus, JM ;

Gage, J ;

Chertow, GM .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (04) :743-749

[10]

Glaspy John A, 2005, Expert Opin Emerg Drugs, V10, P553, DOI 10.1517/14728214.10.3.553

← 1 2 →